ArticleJACC. CardioOncology2026
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.
Article in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiac Biomarker Complete Response in Light Chain Amyloidosis: How Much of the Heart Is Captured?JACC. CardioOncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac biomarker complete response (CR) is a new concept in amyloid light chain (AL) cardiac amyloidosis (CA).
objectivesThe aim of this study was to characterize patients with AL CA who achieved cardiac biomarker CR, including clinical presentation, treatment, cardiac recovery, and survival.
methodsThis single-center retrospective cohort study included patients diagnosed with AL CA between 2004 and 2023 who met cardiac biomarker response eligibility (baseline N-terminal pro-B-type natriuretic peptide [NT-proBNP] >650 pg/mL or B-type natriuretic peptide >150 pg/mL). Among these, patients who achieved cardiac biomarker CR, defined as NT-proBNP ≤350 pg/mL or B-type natriuretic peptide ≤80 pg/mL sustained for at least 12 months, were identified. The median follow-up duration was 9.5 years.
resultsSixty-three patients achieved cardiac biomarker CR (4.7% of evaluable cases [63 of 1,342]). This proportion increased in the second period compared with the first (6.4% [38 of 591] vs 3.3% [25 of 751]; P < 0.001). The median age was 57 years (Q1-Q3: 49-66 years), and 63.5% were men. The median baseline difference between involved and uninvolved free light chains was 429 mg/L (Q1-Q3: 143-708 mg/L), the median pretreatment NT-proBNP concentration was 1,977 pg/mL, and 57.1% of patients were in cardiac stage II. Hematologic CR preceded cardiac biomarker CR in 76% of patients. The median time to cardiac biomarker CR was 20.6 months. At cardiac biomarker CR, the median NT-proBNP concentration was 265 pg/mL (86.9% reduction from baseline). Echocardiographic parameters improved by the time of cardiac biomarker CR but did not fully normalize in all patients. Cardiac progression occurred in 14% of patients, and 44.4% required subsequent clone-directed therapy. Eight patients died, 2 of non-AL CA-related causes. Survival was comparable with that of a matched general U.S. population (P = 0.35).
conclusionsCardiac biomarker CR represents the deepest level of cardiac biochemical recovery in AL amyloidosis and is associated with survival similar to the general population. Despite biochemical recovery, structural cardiac abnormalities may persist, underscoring the importance of early diagnosis and timely therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.